Literature DB >> 22433760

Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review.

Dirk Müller1, Jannis Pulm, Afschin Gandjour.   

Abstract

OBJECTIVES: To compare cost-effectiveness modeling analyses of strategies to prevent osteoporotic and osteopenic fractures either based on fixed thresholds using bone mineral density or based on variable thresholds including bone mineral density and clinical risk factors.
METHODS: A systematic review was performed by using the MEDLINE database and reference lists from previous reviews. On the basis of predefined inclusion/exclusion criteria, we identified relevant studies published since January 2006. Articles included for the review were assessed for their methodological quality and results.
RESULTS: The literature search resulted in 24 analyses, 14 of them using a fixed-threshold approach and 10 using a variable-threshold approach. On average, 70% of the criteria for methodological quality were fulfilled, but almost half of the analyses did not include medication adherence in the base case. The results of variable-threshold strategies were more homogeneous and showed more favorable incremental cost-effectiveness ratios compared with those based on a fixed threshold with bone mineral density. For analyses with fixed thresholds, incremental cost-effectiveness ratios varied from €80,000 per quality-adjusted life-year in women aged 55 years to cost saving in women aged 80 years. For analyses with variable thresholds, the range was €47,000 to cost savings.
CONCLUSIONS: Risk assessment using variable thresholds appears to be more cost-effective than selecting high-risk individuals by fixed thresholds. Although the overall quality of the studies was fairly good, future economic analyses should further improve their methods, particularly in terms of including more fracture types, incorporating medication adherence, and including or discussing unrelated costs during added life-years. Copyright Â
© 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22433760     DOI: 10.1016/j.jval.2011.11.030

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

1.  Modelling the cost effectiveness of interventions for osteoporosis: issues to consider.

Authors:  Matt D Stevenson; Peter L Selby
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

2.  Long-term effects of alendronate on fracture healing and bone remodeling of femoral shaft in ovariectomized rats.

Authors:  Ling-jie Fu; Ting-ting Tang; Yong-qiang Hao; Ke-rong Dai
Journal:  Acta Pharmacol Sin       Date:  2013-02-04       Impact factor: 6.150

Review 3.  Recent advances: osteoporosis in the "oldest old".

Authors:  Cathleen S Colón-Emeric
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

4.  Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study.

Authors:  E Söreskog; F Borgström; L Shepstone; S Clarke; C Cooper; I Harvey; N C Harvey; A Howe; H Johansson; T Marshall; T W O'Neill; T J Peters; N M Redmond; D Turner; R Holland; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2020-04-01       Impact factor: 4.507

5.  Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model.

Authors:  Florian Bleibler; Kilian Rapp; Andrea Jaensch; Clemens Becker; Hans-Helmut König
Journal:  BMC Health Serv Res       Date:  2014-06-30       Impact factor: 2.655

6.  Potential antiosteoporotic agents from plants: a comprehensive review.

Authors:  Min Jia; Yan Nie; Da-Peng Cao; Yun-Yun Xue; Jie-Si Wang; Lu Zhao; Khalid Rahman; Qiao-Yan Zhang; Lu-Ping Qin
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-31       Impact factor: 2.629

Review 7.  Health technology assessment in osteoporosis.

Authors:  Mickael Hiligsmann; John A Kanis; Juliet Compston; Cyrus Cooper; Bruno Flamion; Pierre Bergmann; Jean-Jacques Body; Steven Boonen; Olivier Bruyere; Jean-Pierre Devogelaer; Stefan Goemaere; Jean-Marc Kaufman; Serge Rozenberg; Jean-Yves Reginster
Journal:  Calcif Tissue Int       Date:  2013-03-21       Impact factor: 4.333

8.  National healthcare budget impact analysis of the treatment for osteoporosis and fractures in Korea.

Authors:  Hwabok Yi; Yong-Chan Ha; Young-Kyun Lee; Young-Taik Lim
Journal:  J Bone Metab       Date:  2013-05-13

9.  Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia.

Authors:  Jin-Won Kwon; Hae-Young Park; Ye Jee Kim; Seong-Hwan Moon; Hye-Young Kang
Journal:  J Bone Metab       Date:  2016-05-31

Review 10.  Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review.

Authors:  Shumaila M Iqbal; Iqra Qamar; Cassandra Zhi; Anum Nida; Hafiz M Aslam
Journal:  Cureus       Date:  2019-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.